SuperworthGuardian Pharmacy Services profit margin GRDN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2024.
- Net margin, 12 months
- 4.5%
- Operating margin, 12 months
- 5.8%
- Net margin on a year earlier
- +11.4 pts
- Peer median
- 10.2%
Over the twelve months to Jun 30, 2026, Guardian Pharmacy Services kept 4.5% of its revenue as net profit, with an operating margin of 5.8% and a gross margin of 21.6%.
The median for 10 healthcare stocks of a similar size is 10.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 3.4% | 5.0% | 20.2% |
| FY2024 | −9.0% | −5.1% | 19.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 4.5% | +11.4 pts | 5.8% | |
| Q1 FY26 | 3.6% | +11.5 pts | 5.3% | |
| Q4 FY25 | 3.4% | +12.4 pts | 5.0% | |
| Q3 FY25 | 2.9% | n/a | 4.2% | |
| Q2 FY25 | −6.9% | n/a | −4.7% | |
| Q1 FY25 | −7.8% | n/a | −4.5% | |
| Q4 FY24 | −9.0% | n/a | −5.1% | |
| Q3 FY24 | n/a | n/a | −5.5% | |
| Q2 FY24 | n/a | n/a | 3.0% | |
| Q1 FY24 | n/a | n/a | n/a |
Against its peers
Companies in Healthcare nearest Guardian Pharmacy Services' size, closest first, today.
| Company | Profit margin |
|---|---|
| GRDNGuardian Pharmacy Services | 4.5% |
| TMDXTransMedics | 22.7% |
| ADMAAdma Biologics | 33.0% |
| MDPediatrix Medical | 9.0% |
| UFPTUFP Technologies | 11.4% |
| ADUSAddus HomeCare | 7.1% |
| PBHPrestige Consumer Healthcare | 15.6% |
| NRIXNurix Therapeutics | 42.0% |
| PGNYProgyny | 6.0% |
| PRVAPrivia Health | 1.2% |
| VCELVericel | 7.9% |
| Peer median | 10.2% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Guardian Pharmacy Services
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.